Evidence map›Paper›PMID 40888966›Full record

ArticleClinical and experimental medicine2025

Comprehensive analysis of KRT18 as a novel prognostic biomarker and potential target in lung adenocarcinoma.

Jiajia Xiao, Zhenpeng Zhu, Fengxu Yan, Zhicong Yang, Dandan Xu, Fan Zhang, Xinsheng Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiajia XiaoGraduate School, Hebei North University, Zhangjiakou, 075000, China.
Zhenpeng ZhuGraduate School, Hebei North University, Zhangjiakou, 075000, China.
Fengxu YanGraduate School, Hebei North University, Zhangjiakou, 075000, China.
Zhicong YangCentral Laboratory, The First Affiliated Hospital of Hebei North University, No. 12 Changqing Road, Qiaoxi District, Zhangjiakou, 075000, China.
Dandan XuCentral Laboratory, The First Affiliated Hospital of Hebei North University, No. 12 Changqing Road, Qiaoxi District, Zhangjiakou, 075000, China.
Fan ZhangDepartment of Pathology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075000, China.
Xinsheng WangCentral Laboratory, The First Affiliated Hospital of Hebei North University, No. 12 Changqing Road, Qiaoxi District, Zhangjiakou, 075000, China. wangxinsheng@hbbfyfy.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe expression characteristics of Keratin 18 (KRT18) in lung adenocarcinoma (LUAD) remain incompletely elucidated. This study aims to investigate the expression pattern of KRT18 in LUAD and its prognostic significance.

methodsWe analyzed the expression status of KRT18 in LUAD and its association with prognosis. Utilizing the UALCAN and STRING databases, we systematically evaluated the clinical phenotypic parameters of KRT18 and its protein-protein interaction network. Through enrichment analysis, we clarified its biological functions and associated signaling pathways, and simultaneously deciphered the association patterns between the tumor immune infiltration landscape and immune checkpoint molecules.

resultsHigh expression of KRT18 was associated with poor prognosis in LUAD patients and was closely correlated with tumor stage and pathological stage. Functional enrichment analysis revealed that KRT18 was significantly enriched in epithelial cell differentiation and intermediate filament pathways. Immune infiltration analysis showed that the expression of KRT18 was associated with tumor immune cell infiltration and immune checkpoints. Immunohistochemistry further confirmed the high expression of KRT18 in LUAD tissues.

conclusionTherefore, KRT18 may serve as a biomarker for the prognosis and diagnosis of LUAD and also represents a potential target for immunotherapy.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorKeratin-18Lung NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMiddle AgedPrognosisProtein Interaction MapsBiomarkers, TumorKeratin-18KRT18 protein, humanBioinformaticsClinical prognosisImmune infiltrationKeratin 18Lung adenocarcinoma

Identifiers

PMID40888966
PMCPMC12401774

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.